Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.
This study evaluated combination drug partners for CP-4055, the C18:1(Delta9,trans) unsaturated fatty acid ester of cytarabine in HL-60 and U937 cells. Growth inhibition was assessed by ATP assay and drug interaction by the combination index and three dimensional methods. Synergy was observed in HL-60 cells for simultaneous combinations of CP-4055 with gemcitabine, irinotecan and topotecan, while combinations with cloretazine (VNP40101M) and idarubicin were additive. In U937 cells, synergy was observed with gemcitabine and additivity for the other drugs. In HL-60, the IC50 concentration of CP-4055 could be reduced 10-fold and that of gemcitabine 3-fold in combination versus the agents alone, an interaction that was independent of drug sequence, ratio and exposure time. In contrast, interactions of CP-4055 with the topoisomerase inhibitors became antagonistic when the drugs were administered 24 h prior to CP-4055 and at certain drug ratios, particularly in U937 cells. In summary, CP-4055 produced additive to synergistic anti proliferative activity when combined simultaneously with drugs from four mechanistic classes in cell culture models of human leukemia and lymphoma. The impact of drug sequence and ratio on the interactions argues for incorporation of these parameters into the design of combination chemotherapy regimens.
Adams
David J
DJ
Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA. adams041@mc.duke.edu
Sandvold
Marit L
ML
Myhren
Finn
F
Jacobsen
Tove F
TF
Giles
Frank
F
Rizzieri
David A
DA
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D002166:Camptothecin / Q000031:analogs & derivatives; D045744:Cell Line, Tumor; D003561:Cytarabine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D003841:Deoxycytidine / Q000031:analogs & derivatives; D004347:Drug Interactions; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D006834:Hydrazines; D015255:Idarubicin; D000077146:Irinotecan; D007938:Leukemia / Q000188:drug therapy* / Q000473:pathology; D008223:Lymphoma / Q000188:drug therapy* / Q000473:pathology; D013449:Sulfonamides; D019772:Topotecan; D000093542:Gemcitabine
D006834:Hydrazines; D013449:Sulfonamides; D003561:Cytarabine; D003841:Deoxycytidine; C047645:5'-oleoyl cytarabine; C483604:laromustine; D000077146:Irinotecan; D019772:Topotecan; D002166:Camptothecin; D015255:Idarubicin; D000093542:Gemcitabine